Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Control Bionics Ltd. ( (AU:CBL) ) has shared an update.
Control Bionics Limited has issued 8,443,747 fully paid ordinary shares on 31 December 2025 without a prospectus or product disclosure statement, relying on provisions of the Corporations Act that allow such an issue to be made to certain investors. The company confirmed it is up to date with its financial reporting and continuous disclosure obligations and stated that there is no undisclosed price-sensitive information, signalling that the new share issue is being conducted within the standard regulatory framework and without additional market-moving information for existing shareholders.
The most recent analyst rating on (AU:CBL) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Control Bionics Ltd. stock, see the AU:CBL Stock Forecast page.
More about Control Bionics Ltd.
Control Bionics Limited is an Australian-based medical technology company that develops and sells assistive communication and control solutions, primarily aimed at people with disabilities who have difficulty communicating or interacting with computers and other devices.
Average Trading Volume: 1,133,131
Technical Sentiment Signal: Buy
Current Market Cap: A$25.83M
See more data about CBL stock on TipRanks’ Stock Analysis page.